CEO of TechBio Platform Company Recruited by Occam Global
In October 2024, Occam recruited Thomas McCauley, PhD, as President and CEO of Neptune Bio, a NYC-based TechBio platform company backed by Lux Capital and KdT Ventures.
Tom joins Neptune from Omega Therapeutics, a Flagship incubated epigenetics platform company, where he has served as Chief Scientific Officer (CSO) from the company's infancy through crossover and a public offering.
Previously, Tom served as CSO of Macrolide Pharma and Translate Bio (acquired by Sanofi for $3.2B). He began his industrial career at Shire.
Tom received a BS and MEng in Applied and Engineering Physics from Cornell and his PhD in Condensed Matter and Materials Physics from the University of Alabama.
About Neptune Bio
Neptune Bio is dedicated to discovering combinatorial cures by identifying the distinct conditions that trigger cellular changes. Their platform integrates groundbreaking biological data with advanced artificial intelligence (AI) to model complex gene synergies, paving the way for the development of new combinatorial therapies.
Related Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.